Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) is a global company in analytical and clinical laboratory technologies, and its news flow reflects activity across life sciences, diagnostics, and applied markets. Company announcements highlight how Agilent’s instruments, software, services, and expertise are used to help customers bring great science to life, as well as how it manages its financial performance and corporate governance.
On this page, readers can follow Agilent news related to earnings results, product introductions, regulatory-focused solutions, capital allocation, and investor events. Recent releases include quarterly and full-year financial results, with details on revenue, net income, and segment performance for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These updates often include management commentary on business conditions and outlook.
Agilent’s news also covers product and technology developments. For example, the company has announced 21 CFR Part 11 compliance software for the xCELLigence RTCA eSight system, designed to support use in GMP-regulated manufacturing and quality control environments by adding secure user authentication, electronic signatures, and audit trails. Another announcement introduced Agilent Altura Ultra Inert HPLC Columns, described as high performance liquid chromatography columns suited for biotherapeutics applications such as peptide GLP-1 and oligonucleotide therapeutic development and quality control.
Investors and analysts can also find updates on capital markets activities, such as cash dividend declarations on Agilent’s common stock, and notices of participation in healthcare and investor conferences. Governance-related news, including leadership transitions and executive appointments, is communicated through press releases and related SEC filings. Bookmarking this page allows users to review Agilent’s ongoing communications about its operations, technologies, financial performance, and corporate developments in one place.
Summary not available.
Summary not available.
Agilent Technologies Inc. (NYSE: A) will disclose its financial results and hold an earnings conference call for the second quarter of fiscal year 2023 on May 23, 2023, at 1:30 p.m. PDT.
The conference call will be accessible via a webcast, with a recording available for 90 days thereafter. Last year, Agilent generated $6.85 billion in revenue and employs approximately 18,000 people globally. This event will provide insights into the company’s performance and future outlook.
Agilent Technologies (NYSE: A) showcased innovative solutions in cell analysis, genomics, and digital pathology at the American Association for Cancer Research Annual Meeting from April 14-19, 2023, in Orlando, Florida. With over 1.9 million new cancer cases projected in 2023, Agilent's strategic focus on cancer research aims to empower professionals in the field. Highlights include the launch of the Agilent SureSelect Cancer Comprehensive Genomic Profiling (CGP) Assay for somatic variant detection in solid tumors and a partnership with PathAI to integrate AI into diagnostics. The company also plans to feature presentations on cutting-edge cancer care technologies and ongoing research at its booth. In fiscal 2022, Agilent reported revenue of $6.85 billion and employs approximately 18,000 people globally.
Agilent Technologies (NYSE: A) has launched the SureSelect Cancer CGP Assay, aimed at somatic variant profiling for a wide range of solid tumors. This innovative assay features a panel of 679 globally curated genes and supports various biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI). With an efficient workflow allowing low sample input as low as 10 ng, this assay enhances accessibility for clinical researchers. The assay can be automated, reducing hands-on time from several hours to just 15 minutes. Agilent's focus on precision oncology is underscored by this release and its recent acquisition of Avida Biomed. The company generated $6.85 billion in revenue in fiscal 2022, emphasizing its significant market presence.
Agilent Technologies Inc. (NYSE: A) has entered into a strategic partnership with PathAI to enhance AI-powered assay development for biopharmaceutical companies.
This collaboration aims to combine Agilent's expertise in assay development with PathAI’s advanced algorithms, providing an end-to-end solution for companion diagnostics and precision medicine. As part of this partnership, Agilent will distribute PathAI’s AISight platforms across anatomic pathology laboratories globally.
The multi-year agreement also allows Agilent to commercialize future algorithms launched by PathAI, marking a significant step towards integrating AI in precision oncology.
Agilent generated $6.85 billion in revenue for fiscal 2022, indicating a robust market presence in life sciences and diagnostics.
Summary not available.
Agilent Technologies Inc. (NYSE: A) has launched the Cary 3500 Flexible UV-Vis System, a double-beam spectrophotometer designed for advanced pharmaceutical sample analysis. This new system features a large sample compartment and is suited for both liquid and solid samples, making it ideal for regulated environments like pharma/biopharma. Notably, the system comes with a 10-year warranty on the xenon flash lamp, which significantly reduces replacement costs. Additionally, upgrades to the Cary UV Workstation software enhance data processing efficiency. This innovation builds on the Cary series' success since its 2018 introduction, further solidifying Agilent's portfolio in integrated solutions.
Summary not available.
Agilent Technologies (NYSE: A) has announced Dr. Kathryn Wolhuter as the recipient of the 2023 Darlene Solomon Award, recognizing her impactful research in coronary heart disease at the Victor Chang Cardiac Research Institute. The award, presented during the iSLS11 Symposium in Singapore, aims to promote female scientists in mass spectrometry. Dr. Wolhuter's research focuses on understanding gene functions in cardiovascular disease. The award includes opportunities for further training and networking at Agilent’s Global Solutions Development Center in Singapore. Agilent emphasizes its commitment to supporting women in scientific research.